Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q86TM3 (
cage
)
29,987
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Platelet-activating factor (
PAF
-acether) has been shown to be produced by the kidney and to sharply reduce glomerular filtration rate (GFR) and renal plasma flow (RPF). Thus,
PAF
-acether could be a possible mediator of the reduction of GFR and RPF in ischemic-induced acute renal failure (ARF). We have assayed the effect of inhibiting the interaction of
PAF
-acether with its receptor using two specific
PAF
-acether antagonists, BN-52021 and alprazolam, on the evolution of the GFR and RPF, in the experimental model of ARF induced in rats by clamping the left artery for 60 min. In addition, we have measured arteriovenous differences in
PAF
-acether concentration, as well as
PAF
-acether content in glomeruli from rats with ARF pretreated or not with BN-52021. In metabolic
cage
studies, plasma creatinine increased more in the untreated than in the BN-52021-treated group, whereas creatinine clearance was higher in treated than in untreated rats. In acute clearance experiments, after renal artery clamping, untreated rats showed a marked oliguria and reduction of the inulin clearance (greater than 99%), which showed no recovery 90 min after clamp release, whereas GFR reached values above 0.1 ml/min in the rats treated with BN-52021 or alprazolam, with clearly significant statistical differences. Results of p-aminohippurate clearance were similar to those of GFR. Glomeruli from rats with ARF had greater amounts of
PAF
-acether than glomeruli from normal rats, whereas glomeruli from BN-52021-treated rats with ARF produced intermediate amounts. These results provide evidence for a role for
PAF
-acether in the genesis of this model of experimental ARF.
...
PMID:Platelet-activating factor antagonists treatment protects against postischemic acute renal failure in rats. 232 16
Platelet-activating factor [1-O-alkyl-2-acetyl-sn-glycero-phosphocholine;
PAF
] is a unique signaling phospholipid which has been implicated in a number of biological activities (e.g., reproduction).
PAF
has been detected in the spermatozoa from a number of laboratory and domestic species, including, but not limited to, rabbit, bovine, and the mouse. The concentration of
PAF
is inversely related to human (Homo sapien) spermatozoal quality. Additionally,
PAF
levels are significantly higher in Bolivian squirrel monkey (Saimiri sciureus) spermatozoa obtained during the breeding season than spermatozoa obtained during the nonbreeding season. There are no reports on the presence of
PAF
in rhesus (Macaca mulatta) spermatozoa. Therefore, the primary objective of this study was to detect the presence of
PAF
in rhesus spermatozoa. A second objective was to determine if
PAF
spermatozoa levels differ between animals housed individually (single-caged) versus free-ranging (open corrals). Semen were collected from mature rhesus via electro-ejaculation. Spermatozoa were washed free of ejaculatory plug and quick frozen in PBS. Endogenous lipids were extracted from thawed spermatozoa and ejaculatory plugs then assayed for the presence of
PAF
by [125I]-radioimmunoassay.
PAF
was not detected in any ejaculatory plugs.
PAF
levels were significantly higher (P < 0.01) in spermatozoa obtained from free-ranging males (mean: 1.16 pmol/10(6) spermatozoa) than males housed individually in single
cage
units (mean: 0.53 pmol/10(6) spermatozoa).
PAF
was present in rhesus spermatozoa. Additionally,
PAF
levels were higher in spermatozoa obtained from corral-housed animals. Additional studies are warranted to elucidate the role of
PAF
in spermatozoa function.
...
PMID:Presence of platelet-activating factor in rhesus (Macaca mulatta) spermatozoa. 1037 38